Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM

ESC 2025

Cardiovascular Risk and Diseases

Mavacamten monotherapy demonstrates sustained clinical benefits in obstructive hypertrophic cardiomyopathy

Heart, Artery and Coronary Diseases

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

N Engl J Med

Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, MAPLE-HCM Investigators

doi: 10.1056/NEJMoa2504654

Heart, Artery and Coronary Diseases

Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial

J Am Coll Cardiol

Desai MY, Olivotto I, Abraham T, Nissen SE, Garcia-Pavia P, Lopes RD, Elliott PM, Fernandes F, de Barros Correia E, Barriales-Villa R, Zorio E, Arad M, Shin SH, Verheyen N, Meder B, Azevedo O, Kitaoka H, Wolski K, Wang Q, Suryawanshi B, Wang Z, Florea V, Aronson R, Owens AT, ODYSSEY-HCM Investigators

doi: 10.1016/j.jacc.2025.08.017

Heart Failure

Association of a remote monitoring programme with all-cause mortality and hospitalizations in patients with heart failure: National-scale, real-world evidence from a 3-year propensity score analysis of the TELESAT-HF study

Eur J Heart Fail

Girerd N, Barbet V, Seronde MF, Benchimol H, Jagu A, Tartière JM, Hanon O, Picard F, Lafitte S, Lemaitre M, Pages N, Nisse-Durgeat S, Jourdain P

doi: 10.1002/ejhf.3563

Heart Failure

Real-world outcomes in cardiac resynchronization therapy patients: Primary results of the SMART registry

ESC Heart Fail

García-Bolao I, Gardner RS, Gras D, D'Onofrio A, Mark G, Nair D, Lellouche N, Novak M, Lo R, Chew E, Wright D, Kaplan A, Bertini M, Veraghtert S, Harbin MM, Matznick E, Yong P, Stein KM

doi: 10.1002/ehf2.15190

Heart Failure

Predicting Heart Failure Outcomes Using Patient-Reported Health Status: Real-World Validation of the KCCQ-12

J Am Coll Cardiol

El-Sabawi BR, Al-Garadi MA, Steitz BD, Perkins AM, McCoy AB, Sengstack DG, Greevy RA Jr, Burnell EH, Schlendorf KH, Lindenfeld J, Stevenson LW, Gupta DK, Spertus JA, Collins SP, Matheny ME, Bachmann JM

doi: 10.1016/j.jacc.2025.03.545

Heart Failure

Prognosis After >50% Decline in eGFR in Heart Failure Patients: A Nationwide Real-World Study

JACC Heart Fail

Anjum DZ, Elmegaard M, Garred CH, Nouhravesh N, Fosbol E, Jhund PS, McMurray JJV, Petrie MC, Køber L, Schou M

doi: 10.1016/j.jchf.2025.02.027

Heart Failure

Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study

Clin Res Cardiol

Ojeda-Fernández L, Torrigiani G, Molteni M, Fortino I, Cimminiello C, Baviera M

doi: 10.1007/s00392-025-02674-9

Atrial Fibrillation

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry

Clin Res Cardiol

Menichelli D, Gazzaniga G, Poli D, Palareti G, Antonucci E, Pani A, Pignatelli P, Pastori D, START2 Register Investigators

doi: 10.1007/s00392-025-02765-7

Related content

Mavacamten monotherapy demonstrates sustained clinical benefits in obstructive hypertrophic cardiomyopathy

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial

Association of a remote monitoring programme with all-cause mortality and hospitalizations in patients with heart failure: National-scale, real-world evidence from a 3-year propensity score analysis of the TELESAT-HF study

Real-world outcomes in cardiac resynchronization therapy patients: Primary results of the SMART registry

Predicting Heart Failure Outcomes Using Patient-Reported Health Status: Real-World Validation of the KCCQ-12

Prognosis After >50% Decline in eGFR in Heart Failure Patients: A Nationwide Real-World Study

Impact of glp-1 receptor agonists on hospitalization for heart failure and all-cause death in patients with diabetes with and without heart failure: a real-world study

Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry